
Jimena Vicencio
MD
Writer · HealthTree Foundation
4 years of experience · 355 articles · 10 medically reviewed on HealthTree
Jimena is a medical doctor currently studying a bachelor in journalism.
Areas of expertise
- scientific language
- human rights
- journalism
- advocacy
- medicine
- hematology-oncology
- medical education
- literature review
- editorial review
- fact-checking
- ethics
- medical deontology
- social determinants of health
About Jimena
Jimena is a member of the HealthTree Writing team. With an MD background and currently pursuing a bachelor's degree in journalism, she combines her medical knowledge with a storyteller’s heart to make complex healthcare topics accessible to everyone. Driven by a deep belief that understanding health is a universal right, she is passionate about empowering individuals to take control of their well-being.
Jimena's personal connection
As a medical student it was very frustrating to see how little time there is to fully explain a disease to a person who is fearful of their health status. Scientific communications help patients and healthcare providers by providing evidence-based resources, that help calm the uncertainty in people experiencing an illness.
Education
- Medicine Universidad de Guadalajara, 2014
- Medicine Ebehard Karls Universität Tübingen, 2018
- Journalism Universidad de Guadalajara, 2022
Articles by Jimena
See all 355
Ultra Low Doses of Radiation Therapy May Relieve Bone Pain From Multiple MyelomaNov 20, 2026
FDA Approval: Giredestrant (Wilserdly) with Everolimus for ER-positive, HER2-negative, ESR1-mutated Locally Advanced or Metastatic Breast CancerNov 18, 2026
Divesiran: A New Treatment for Polycythemia Vera Under InvestigationNov 16, 2026
Is Myelodysplastic Syndrome (MDS) Cancer?Nov 11, 2026
¿Cuáles son los primeros signos del mieloma múltiple?Nov 09, 2026
CDC 2026–2027 COVID-19 Vaccines: What Cancer Patients Need to KnowNov 04, 2026
Medically reviewed by Jimena
See all 10
A New Vaccine Could Improve Survival for People with AMLNov 20, 2026
FDA Approval: Neladalkib for ALK-positive Non-Small Cell Lung CancerNov 18, 2026
FDA Approval: Amivantamab and Hyluronidase (Rybrevant Faspro) for Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNov 18, 2026
FDA Approval: Durvalumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder CancerNov 17, 2026
¿El mieloma múltiple es hereditario?Nov 17, 2026
Multiple Myeloma Skin Symptoms: Lesions, Lumps, and Other ChangesNov 13, 2026